Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Bausch Health Companies Inc (NYSE: BHC) closed at $7.79 in the last session, down -2.87% from day before closing price of $8.02. In other words, the price has decreased by -$2.87 from its previous closing price. On the day, 2.79 million shares were traded. BHC stock price reached its highest trading level at $8.02 during the session, while it also had its lowest trading level at $7.64.
Ratios:
We take a closer look at BHC’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.72. For the most recent quarter (mrq), Quick Ratio is recorded 0.98 and its Current Ratio is at 1.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on August 02, 2024, Downgraded its rating to Underweight and sets its target price to $3 from $9 previously.
On July 10, 2024, Raymond James started tracking the stock assigning a Mkt Perform rating and target price of $8.
Jefferies Upgraded its Hold to Buy on September 20, 2023, whereas the target price for the stock was revised from $9 to $16.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 14 ’25 when Paulson John bought 34,721,118 shares for $9.00 per share. The transaction valued at 312,490,062 led to the insider holds 70,755,869 shares of the business.
Paulson John bought 2,000,000 shares of BHC for $12,700,000 on Aug 11 ’25. The Director now owns 34,791,702 shares after completing the transaction at $6.35 per share. On Aug 12 ’25, another insider, Paulson John, who serves as the Director of the company, bought 1,156,640 shares for $6.88 each. As a result, the insider paid 7,957,683 and bolstered with 35,948,342 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BHC now has a Market Capitalization of 2880664320 and an Enterprise Value of 23802667008. As of this moment, Bausch’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.74, and their Forward P/E ratio for the next fiscal year is 1.83. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29. Its current Enterprise Value per Revenue stands at 2.415 whereas that against EBITDA is 7.654.
Stock Price History:
The Beta on a monthly basis for BHC is 0.48, which has changed by 0.33619213 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, BHC has reached a high of $9.85, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is 21.20%, while the 200-Day Moving Average is calculated to be 16.45%.
Shares Statistics:
According to the various share statistics, BHC traded on average about 2.79M shares per day over the past 3-months and 7143200 shares per day over the past 10 days. A total of 369.75M shares are outstanding, with a floating share count of 291.98M. Insiders hold about 21.04% of the company’s shares, while institutions hold 67.65% stake in the company. Shares short for BHC as of 1753920000 were 7286725 with a Short Ratio of 2.61, compared to 1751241600 on 8323683. Therefore, it implies a Short% of Shares Outstanding of 7286725 and a Short% of Float of 2.1300000999999997.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.66, with high estimates of $3.76 and low estimates of $0.96.
Analysts are recommending an EPS of between $3.97 and $2.94 for the fiscal current year, implying an average EPS of $3.65. EPS for the following year is $4.26, with 6.0 analysts recommending between $4.85 and $3.65.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $2.61B. It ranges from a high estimate of $2.64B to a low estimate of $2.59B. As of the current estimate, Bausch Health Companies Inc’s year-ago sales were $2.51BFor the next quarter, 5 analysts are estimating revenue of $2.71B. There is a high estimate of $2.77B for the next quarter, whereas the lowest estimate is $2.66B.
A total of 6 analysts have provided revenue estimates for BHC’s current fiscal year. The highest revenue estimate was $10.18B, while the lowest revenue estimate was $10.04B, resulting in an average revenue estimate of $10.1B. In the same quarter a year ago, actual revenue was $9.62BBased on 6 analysts’ estimates, the company’s revenue will be $10.4B in the next fiscal year. The high estimate is $10.7B and the low estimate is $9.98B.
